I read with interest the article by Schattner and Liang1 regarding the cardiovascular burden of lupus. Cardiovascular diseases secondary to accelerated atherosclerosis are now accepted as an important cause of mortality and morbidity in patients with systemic lupus erythematosus (SLE). Lowering cholesterol levels with statin therapy is one of the main targets to reduce the morbidity and mortality of SLE.2 However, these lipid-lowering agents may have unexpected immunologic effects.
Noël B. Risks and Benefits of Statins in Lupus Erythematosus. Arch Intern Med. 2004;164(1):107-108. doi:10.1001/archinte.164.1.107-b